Evidence map›Paper›PMID 39713939›Full record

GuidelineAlzheimer's & dementia : the journal of the Alzheimer's Association2025

The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instruments.

Alireza Atri, Bradford C Dickerson, Carolyn Clevenger, Jason Karlawish, David Knopman, Pei-Jung Lin, Mary Norman, Chiadi Onyike, Mary Sano, Susan Scanland and 1 more

Registry-linked trialAbstract readPractice Guideline
In one paragraph

Guideline in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07630688 (Turkish Validity and Reliability Study of the MoCA-B Test), which is not on this map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07630688 completednot on this map

Turkish Validity and Reliability Study of the MoCA-B Test

TypeobservationalSponsorAntalya Training and Research HospitalRan2024 to 2026Enrolled166ConditionsBehavioral and Psychological Symptoms of Dementia, Dementia, Dementia (Diagnosis), Dementia Alzheimer Type
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Guideline
  4. Trial
  5. Review
  6. Article
  7. Natriuretic Peptides as a Biomarker of Cognitive Decline in Hypertension.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Functional capacity in Peruvian people with Alzheimer's disease and frontotemporal dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Donanemab: Appropriate use recommendations.The journal of prevention of Alzheimer's disease · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alireza AtriBanner Sun Health Research Institute and Banner Alzheimer's Institute, Sun City, Arizona, USA.
Bradford C DickersonFrontotemporal Disorders Unit and Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Carolyn ClevengerDepartment of Neurology, Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia, USA.
Jason KarlawishDepartments of Medicine, Medical Ethics and Health Policy, and Neurology, Perelman School of Medicine, Penn Memory Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
David KnopmanDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Pei-Jung LinCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.
Mary NormanCedars-Sinai Medical Center, Culver City, California, USA.
Chiadi OnyikeDivision of Geriatric Psychiatry and Neuropsychiatry, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Mary SanoJames J. Peters VAMC, Bronx, New York, USA.
Susan ScanlandDementia Connection, Clarks Summit, Pennsylvania, USA.
Maria CarrilloMedical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI ALIREZA ATRI · 2021 to 2026
$24.9M
Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Alzheimer's AssociationNIA NIH HHS P30 AG062421NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG072980
6 · The paper itself

Abstract

US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's Disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence-based guideline was developed to empower all-including primary care-clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. As part of the modified Delphi approach and guideline development process (7374 publications were reviewed; 133 met inclusion criteria) an expert workgroup developed recommendations as steps in a patient-centered evaluation process. The workgroup provided a summary of validated instruments to measure symptoms in daily life (including cognition, mood and behavior, and daily function) and to test for signs of cognitive impairment in the office. This article distills this information to provide a resource to support clinicians in the implementation of this approach in clinical practice. The companion articles provide context for primary care and specialty clinicians with regard to how to fit these instruments into the workflow and actions to take when integration of performance on these instruments with clinical profile and clinician judgment support potential cognitive impairment.

Indexed as

Alzheimer DiseaseCognitive DysfunctionDisclosureDelphi TechniqueHumansNeuropsychological TestsAlzheimer's diseasecerebrospinal fluiddementiadiagnosisfrontotemporal dementiaLewy body dementiamagnetic resonance imagingmild cognitive impairmentmolecular biomarkerspositron emission tomographyvascular cognitive impairment

Identifiers

PMID39713939
PMCPMC11772712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.